Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.

Alessio AghemoMarcello PersicoRoberta D'AmbrosioMassimo AndreoniErica VillaAbhi BhagatValentina GallinaroGiuliana GualbertiRocco Cosimo Damiano MerollaAntonio Gasbarrini

Published in: PloS one (2023)

Results from this real-world Italian cohort demonstrated the safety and effectiveness of 8-week G/P, with SVR12 rate >95%, even in elderly patients. These findings further support real-world evidence of the use of short-course G/P treatment in all patients with CC, including those with GT3, and those with advanced liver disease.

Keyphrases

end stage renal disease
randomized controlled trial
systematic review
ejection fraction
newly diagnosed
chronic kidney disease
hepatitis c virus
peritoneal dialysis
gestational age